// App-Quantinova.ai

12043 : Predictive tools for bevacizumab therapy in patients with aggressive HER 2-negative metastatic breast cancer: 2-years results from an observational study.

Researchers

Presenter

  • Encarnacion Gonzalez Flores

Principal Investigators

  • Isabel Alvarez

  • Luis Manso

  • Jose Luis Alonso Romero

  • Juan J. Cruz-Hernandez

  • Vicente Caranana

  • Isabel Gallegos

  • Maria Quindos Varela

  • Jose Juan Illarramendi

  • Elena Vicente

  • Ana Isabel Ballesteros Garcia

  • Antonia Perello

  • Antonio Llombart-Cussac

  • Analia Adela Rodriguez

  • Jose Vidal-Martinez

Medical Centers

  • H. Virgen de las Nieves, Granada, Spain

  • Hospital Donostia, San Sebastian, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain

  • Complejo Asistencial Universitario de Salamanca, Oncology Department, Head of Department, Salamanca, Spain

  • Hospital Arnau Vilanova, Valencia, Spain

  • Complejo Asistencial de Segovia, Segovia, Spain

  • Oncology Service, Complejo Hospitalario Universitario A Coruna, A Coruna, Spain

  • Hospital de Navarra, Pamplona, Spain

  • Complejo Hospitalario Insular, Las Palmas De Gran Canaria, Spain

  • Hospital Universitario La Paz, Madrid, Spain

  • Hospital Universitario Son Espases, Palma de Mallorca, Spain

  • Hospital Arnau Vilanova, Valencia, Spain

  • Hospital Arnau de Vilanova de Valencia, Valencia, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Bevacizumab

Outcome

  • Unknown

Study Design

  • Observational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved